Improving and Accelerating Therapeutic Development for Nervous System Disorders

Improving and Accelerating Therapeutic Development for Nervous System Disorders
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 118
Release: 2014-02-06
ISBN: 0309292492
Category: Medical
Language: EN, FR, DE, ES & NL

Improving and Accelerating Therapeutic Development for Nervous System Disorders Book Excerpt:

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Drug Discovery for Nervous System Diseases

Drug Discovery for Nervous System Diseases
Author: Franz Hefti
Publsiher: Wiley-Liss
Total Pages: 319
Release: 2005
ISBN: 1928374650XXX
Category: Medical
Language: EN, FR, DE, ES & NL

Drug Discovery for Nervous System Diseases Book Excerpt:

The book focuses on drug discovery for psychiatric and neurological diseases, which is in a phase of explosive growth. Chapters are divided into two major sections. The first section presents fundamentals of drug discovery, highlighting the modern techniques and approaches of drug discovery in biotech and pharmaceutical companies.

Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders

Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders
Author: National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 94
Release: 2017-05-24
ISBN: 0309455162
Category: Medical
Language: EN, FR, DE, ES & NL

Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders Book Excerpt:

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop.

Improving the Utility and Translation of Animal Models for Nervous System Disorders

Improving the Utility and Translation of Animal Models for Nervous System Disorders
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 110
Release: 2013-03-25
ISBN: 030926636X
Category: Medical
Language: EN, FR, DE, ES & NL

Improving the Utility and Translation of Animal Models for Nervous System Disorders Book Excerpt:

Nervous system diseases and disorders are highly prevalent and substantially contribute to the overall disease burden. Despite significant information provided by the use of animal models in the understanding of the biology of nervous system disorders and the development of therapeutics; limitations have also been identified. Treatment options that are high in efficacy and low in side effects are still lacking for many diseases and, in some cases are nonexistent. A particular problem in drug development is the high rate of attrition in Phase II and III clinical trials. Why do many therapeutics show promise in preclinical animal models but then fail to elicit predicted effects when tested in humans? On March 28 and 29, 2012, the Institute of Medicine Forum on Neuroscience and Nervous System Disorders convened the workshop "Improving Translation of Animal Models for Nervous System Disorders" to discuss potential opportunities for maximizing the translation of new therapies from animal models to clinical practice. The primary focus of the workshop was to examine mechanisms for increasing the efficiency of translational neuroscience research through discussions about how and when to use animal models most effectively and then best approaches for the interpretation of the data collected. Specifically, the workshop objectives were to: discuss key issues that contribute to poor translation of animal models in nervous system disorders, examine case studies that highlight successes and failures in the development and application of animal models, consider strategies to increase the scientific rigor of preclinical efficacy testing, explore the benefits and challenges to developing standardized animal and behavioral models. Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary also identifies methods to facilitate development of corresponding animal and clinical endpoints, indentifies methods that would maximize bidirectional translation between basic and clinical research and determines the next steps that will be critical for improvement of the development and testing of animal models of disorders of the nervous system.

Cyclic Nucleotide Phosphodiesterases in the Central Nervous System

Cyclic Nucleotide Phosphodiesterases in the Central Nervous System
Author: Nicholas J. Brandon,Anthony R. West
Publsiher: John Wiley & Sons
Total Pages: 400
Release: 2014-03-07
ISBN: 1118836308
Category: Medical
Language: EN, FR, DE, ES & NL

Cyclic Nucleotide Phosphodiesterases in the Central Nervous System Book Excerpt:

This book reviews advances in understanding phosphodiesteraseswithin the central nervous system and their therapeuticapplications. A range of expert authors from both academia andindustry describe these, then focus on the areas of greatestscientific and medical interest to provide more detailed coverage.Therapeutic and drug discovery applications are covered fordiseases including Alzheimer's, Parkinson's, schizophrenia,erectile dysfunction, and spinal cord injuries. There is also achapter on drug discovery tools such as in vitro assays and X-raystructures for medicinal chemistry studies.

Modern CNS Drug Discovery

Modern CNS Drug Discovery
Author: Rudy Schreiber
Publsiher: Springer Nature
Total Pages: 283
Release: 2021-06-17
ISBN: 3030623513
Category: Medical
Language: EN, FR, DE, ES & NL

Modern CNS Drug Discovery Book Excerpt:

This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book’s final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.

Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders

Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Drug Discovery, Development, and Translation,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 128
Release: 2015-10-22
ISBN: 0309373263
Category: Medical
Language: EN, FR, DE, ES & NL

Financial Incentives to Encourage Development of Therapies That Address Unmet Medical Needs for Nervous System Disorders Book Excerpt:

The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.

Phytochemical Drug Discovery for Central Nervous System Disorders

Phytochemical Drug Discovery for Central Nervous System Disorders
Author: Chukwuebuka Egbuna,Mithun Rudrapal
Publsiher: John Wiley & Sons
Total Pages: 550
Release: 2021-08-17
ISBN: 9781119794097
Category: Medical
Language: EN, FR, DE, ES & NL

Phytochemical Drug Discovery for Central Nervous System Disorders Book Excerpt:

With a focus on herbal and natural product sources for new drugs, this book offers researchers and professionals valuable information about promising leads for effectively targeting and treating CNS disorders. • Presents comprehensive information on the biochemistry of the CNS, the various CNS disorders, and FDA approved drugs • Details drug discovery opportunities from medicinal plants against CNS disorders • Presents the application of computational techniques for drug discovery against CNS disorders

Drug Repositioning

Drug Repositioning
Author: Joel Dudley,Laura Berliocchi
Publsiher: CRC Press
Total Pages: 313
Release: 2017-07-14
ISBN: 1482220849
Category: Medical
Language: EN, FR, DE, ES & NL

Drug Repositioning Book Excerpt:

Nervous system diseases represent a major health concern worldwide. Although important financial and professional investment, their etiology and pathophysiology still remain mostly elusive. Moreover, the clinical need of disease-modifying therapies is still unmet. In the last decades, traditional R&D has failed in identifying new effective therapies in many medical areas and drug repositioning has recently emerged as a promising alternative strategy to de novo drug discovery to improve and accelerate therapeutic development. For the first time, Drug Repositioning: Approaches and Applications for Neurotherapeutics reviews history and advances in drug repositioning, with a special focus on therapeutics for nervous system diseases. International experts from Academia, Industry and Non-profit organisations will provide different views on drug repositioning advantages, challenges and specific applications, which will be covered for nervous system diseases including Alzheimer's, Parkinson's, Huntington's diseases, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, ischemic stroke, and psychiatric disorders. This book provides a balanced overview and synthesis of drug repositioning concept, methods and applications for neurotherapeutics. It represents a valuable resource for students, scientists and clinicians working in academic settings, industry and government agencies within the fields of neuroscience, pharmacology, neurology, pharmaceutical sciences, drug discovery and development.

Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 8

Frontiers in Clinical Drug Research   CNS and Neurological Disorders  Volume 8
Author: Atta-ur-Rahman,Zareen Amtul
Publsiher: Bentham Science Publishers
Total Pages: 174
Release: 2020-11-03
ISBN: 9811470065
Category: Medical
Language: EN, FR, DE, ES & NL

Frontiers in Clinical Drug Research CNS and Neurological Disorders Volume 8 Book Excerpt:

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The eighth volume of this series features reviews that cover the following topics related to the treatment of a variety of CNS disorders, related diseases and basic research: - Emerging Innovative Therapies of Spinal Muscular Atrophy: Current Knowledge and Perspectives - Obesity Induced by The Neurological Drugs - Molecular Mechanism of Nervous System Disorders and Implications for New Therapeutic Targets - Glioma Imaging and Novel Agents - Screening Models for Neuroleptic Drug-Induced Hyperprolactinemia: A Mini-Review.

Frontiers in Clinical Drug Research CNS and Neurological Disorders

Frontiers in Clinical Drug Research   CNS and Neurological Disorders
Author: Atta-ur-Rahman
Publsiher: Bentham Science Publishers
Total Pages: 375
Release: 2015-05-31
ISBN: 1681082950
Category: Science
Language: EN, FR, DE, ES & NL

Frontiers in Clinical Drug Research CNS and Neurological Disorders Book Excerpt:

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The fourth volume of this series features reviews that cover a variety of topics including: -Multiple sclerosis drug therapy -Treatment of diabetic neuropathy -Migraine treatments -Ischemic stroke treatments

Diseases of the Nervous System

Diseases of the Nervous System
Author: Harald Sontheimer
Publsiher: Elsevier
Total Pages: 500
Release: 2021-05-20
ISBN: 0128213965
Category: Medical
Language: EN, FR, DE, ES & NL

Diseases of the Nervous System Book Excerpt:

The study of the brain continues to expand at a rapid pace providing fascinating insights into the basic mechanisms underlying nervous system illnesses. New tools, ranging from genome sequencing to non-invasive imaging, and research fueled by public and private investment in biomedical research has been transformative in our understanding of nervous system diseases and has led to an explosion of published primary research articles. Diseases of the Nervous System, Second Edition, summarizes the current state of basic and clinical knowledge for the most common neurological and neuropsychiatric conditions. In a systematic progression, each chapter covers either a single disease or a group of related disorders ranging from static insults to primary and secondary progressive neurodegenerative diseases, neurodevelopmental illnesses, illnesses resulting from nervous system infection and neuropsychiatric conditions. Chapters follow a common format and are stand-alone units, each covering disease history, clinical presentation, disease mechanisms and treatment protocols. Dr. Sontheimer also includes two chapters which discuss common concepts shared among the disorders and how new findings are being translated from the bench to the bedside. In a final chapter, he explains the most commonly used neuroscience jargon. The chapters address controversial issues in current day neuroscience research including translational research, drug discovery, ethical issues, and the promises of personalized medicine. This new edition features new chapters on Pain and Addiction to highlight the growing opioid crisis and the ethical issue of prescriptions drug abuse. This book provides an introduction for course adoption and an introductory tutorial for students, scholars, researchers and medical professionals interested in learning the state of the art concerning our understanding and treatment of diseases of the nervous system. Each chapter includes suggested further readings and/or journal club recommendations. 2016 PROSE Award winner of the Best Textbook Award in Biological and Life Sciences Provides a focused tutorial introduction to the core diseases of the nervous system Includes comprehensive introductions to Stroke, Epilepsy, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, Head and Spinal Cord Trauma, Multiple Sclerosis, Brain Tumors, Depression, Schizophrenia and many other diseases of the nervous system Covers more than 40 diseases from the foundational science to the best treatment protocols Includes discussions of translational research, drug discovery, personalized medicine, ethics, and neuroscience New Edition features two new chapters on Pain and Addiction

Brain Drug Targeting

Brain Drug Targeting
Author: William M. Pardridge
Publsiher: Cambridge University Press
Total Pages: 353
Release: 2001-05-31
ISBN: 0521800773
Category: Medical
Language: EN, FR, DE, ES & NL

Brain Drug Targeting Book Excerpt:

This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting.

Frontiers in Clinical Drug Research CNS and Neurological Disorders

Frontiers in Clinical Drug Research   CNS and Neurological Disorders
Author: Atta-ur- Rahman
Publsiher: Bentham Science Publishers
Total Pages: 290
Release: 2017-12-21
ISBN: 1681085852
Category: Science
Language: EN, FR, DE, ES & NL

Frontiers in Clinical Drug Research CNS and Neurological Disorders Book Excerpt:

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology. The fifth volume of this series features reviews that cover the following topics: -drug treatment for spinal cord injury -action tremors -natural products for Alzheimer’s disease treatment -non pharmacological approaches towards pain management -biosensors for detecting neurodegenerative diseases -NMDA receptor targeting -alkaloid antidepressants

Glutamate Related Biomarkers in Drug Development for Disorders of the Nervous System

Glutamate Related Biomarkers in Drug Development for Disorders of the Nervous System
Author: Institute of Medicine,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 74
Release: 2011-07-05
ISBN: 0309212243
Category: Medical
Language: EN, FR, DE, ES & NL

Glutamate Related Biomarkers in Drug Development for Disorders of the Nervous System Book Excerpt:

Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System: Workshop Summary investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.

Animal and Translational Models for CNS Drug Discovery Neurological Disorders

Animal and Translational Models for CNS Drug Discovery  Neurological Disorders
Author: Robert A. McArthur,Franco Borsini
Publsiher: Academic Press
Total Pages: 416
Release: 2008-11-18
ISBN: 9780080920382
Category: Medical
Language: EN, FR, DE, ES & NL

Animal and Translational Models for CNS Drug Discovery Neurological Disorders Book Excerpt:

Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasis on what results mean to the overall drug discovery process Exploration of issues in clinical trial design and conductance in each therapeutic area

Neurotherapeutics

Neurotherapeutics
Author: Linda Pullan,Jitendra Patel
Publsiher: Humana Press
Total Pages: 434
Release: 2013-01-06
ISBN: 9781475759785
Category: Medical
Language: EN, FR, DE, ES & NL

Neurotherapeutics Book Excerpt:

Neuroscience's inherent complexity and rapid growth mean that no one can keep abreast of all the changes across the field. We each bring a necessarily narrow perspective. Neurotherapeutics: Emerg ing Strategies is an attempt to provide some diverse perspectives within the hunt for new drugs to treat central nervous system diseases. The book's premise is that the search for new drugs is based on an understanding ofboth clinical and basic sciences. Neurotherapeu tics: Emerging Strategies begins with psychiatry and concludes with neurological disorders. Each chapter examines a disease, including clinical features and existing treatments, but the emphasis is on current concepts of underlying causes and novel strategies for drug discovery arising from these possible mechanisms. Participating authors include basic neuroscientists, industry-based pharmacolo gists and chemists, and clinicians. The chapters describe the status of the existing disease treat ments, and when treatments are lacking, the approach is more basic science oriented. When there is a long history of treatment, there is greater emphasis on those therapies. However, all the chapters seem to reflect the benefits of cloning, since the availability of receptor subtypes now promises the opportunity for greater specificity of drug effects. Modulation of second messengers is another new and recur ring theme. And in the chapter on cachexia, cytokines are explored both as drugs and drug targets. Neurotherapeutics: Emerging Strategies reflects the complex ity of the nervous system, but the overriding message is hope for new and better drugs to treat those diseases that rob us of ourselves.

Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood Brain Barrier

Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood     Brain Barrier
Author: National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Sciences Policy,Forum on Neuroscience and Nervous System Disorders
Publsiher: National Academies Press
Total Pages: 72
Release: 2018-05-29
ISBN: 0309473101
Category: Medical
Language: EN, FR, DE, ES & NL

Enabling Novel Treatments for Nervous System Disorders by Improving Methods for Traversing the Blood Brain Barrier Book Excerpt:

Despite substantial advances in developing treatments for the serious illnesses that affect people worldwide, there remains a tremendous unmet need in the treatment of complex neurologic diseases, including neuropsychiatric and neurodegenerative disorders. Chief among the challenges that have hindered the development of therapeutics for central nervous system (CNS) disorders is the bloodâ€"brain barrier (BBB). The Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop to explore the challenges associated with the BBB that have thus far stymied development of CNS drugs, examine new technologies that could address these challenges, and highlight potential opportunities for moving the field forward. This publication summarizes the presentations and discussions from the workshop.

Neurotherapeutics

Neurotherapeutics
Author: Linda M. Pullan,Jitendra Patel
Publsiher: Humana
Total Pages: 434
Release: 1995-11-13
ISBN: 9780896033061
Category: Medical
Language: EN, FR, DE, ES & NL

Neurotherapeutics Book Excerpt:

Neuroscience's inherent complexity and rapid growth mean that no one can keep abreast of all the changes across the field. We each bring a necessarily narrow perspective. Neurotherapeutics: Emerg ing Strategies is an attempt to provide some diverse perspectives within the hunt for new drugs to treat central nervous system diseases. The book's premise is that the search for new drugs is based on an understanding ofboth clinical and basic sciences. Neurotherapeu tics: Emerging Strategies begins with psychiatry and concludes with neurological disorders. Each chapter examines a disease, including clinical features and existing treatments, but the emphasis is on current concepts of underlying causes and novel strategies for drug discovery arising from these possible mechanisms. Participating authors include basic neuroscientists, industry-based pharmacolo gists and chemists, and clinicians. The chapters describe the status of the existing disease treat ments, and when treatments are lacking, the approach is more basic science oriented. When there is a long history of treatment, there is greater emphasis on those therapies. However, all the chapters seem to reflect the benefits of cloning, since the availability of receptor subtypes now promises the opportunity for greater specificity of drug effects. Modulation of second messengers is another new and recur ring theme. And in the chapter on cachexia, cytokines are explored both as drugs and drug targets. Neurotherapeutics: Emerging Strategies reflects the complex ity of the nervous system, but the overriding message is hope for new and better drugs to treat those diseases that rob us of ourselves.

Principles of CNS Drug Development

Principles of CNS Drug Development
Author: John Kelly
Publsiher: John Wiley & Sons
Total Pages: 324
Release: 2009-10-27
ISBN: 9780470682913
Category: Medical
Language: EN, FR, DE, ES & NL

Principles of CNS Drug Development Book Excerpt:

This title acts as a primer, giving students and newcomers to the field an opportunity to learn about the breadth of the CNS drug discovery. The book outlines the core processes in drug discovery and development for CNS disorders, from evaluating drugs for desirable efficacy, safety and pharmacokinetic features in preclinical (using in vitro and in vivo models) and clinical experimentation to identifying future drug targets. Containing up-to-date experimental evidence and detailing the main impediments in the pipeline of CNS drug discovery and development, this is a key reference for those involved in all stages of CNS drug discovery. Key Features: Discusses in detail the key stages of CNS drug discovery, outlining the particular requirements and obstacles for CNS drugs Addresses safety concerns and future drug targets Provides succinct background information about the major CNS diseases Examples of specific drugs are used throughout to describe the development of a new drug from conception to clinical use and post-market surveillance Primary reasons for drug failure are given for each stage